Bionik Laboratories Corp. · OTC:BNKL
Bionik Laboratories — Investor Presentation (November 2016)
25 slides from Bionik Laboratories's investor presentation, Nov 1, 2016
Slide 1: Investor Presentation November 2016
Investor Presentation November 2016 www.bioniklabs.com OTCQX:BNKL
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation contains forward - looking statements relating to future events or the future financial performance and operations of Bionik . Forward - looking statements, which involve assumptions and describe Bionik’s intent, belief or current expectations about its business op
Slide 3: Corporate Overview
3 Corporate Overview • Bionik Labs was founded in 2011 by Michal Prywata and Thiago Caires • Robotics company developing solutions for neurological disorders • Primary program exoskeleton assistive technology (ARKE) • Bionik acquired Interactive Motion Technologies (IMT) in April 2016 • IMT was foun
Slide 4: Bionik Vision and Mission
4 Bionik Vision and Mission • Build a company with substantial year - over - year revenue growth within five years • Growth achieved both organically through internal development and externally through partnerships, licensing & acquisitions • Differentiation through compelling clinical data to suppo
Slide 5: Bionik Investment Highlights
5 Bionik Investment Highlights Large and Growing Patient Treatment Indications Emergence of Rehabilitation Robotics Category Advanced Platform Technologies for Upper and Lower Extremity in Market Currently Extensive Clinical Data Supporting Efficacy and Cost Savings Deep Product Pipeline to Leverage
Slide 6: This is a Big Opportunity
6 This is a Big Opportunity 6 2018 2018 2017 US Units Europe Units ROW Units ANNUAL UNITS Average Selling Price TOTAL ADDRESSABLE ANNUAL MARKET (TAM) InMotion Clinic InMotion Home ARKE Home ARKE Clinic 1,620 1,620 4,860 8,100 225,000 225,000 450,000 900,000 30,000 30,000 60,000 120,000 540 540 1,620
Slide 7: Global Health Problems are Growing Rapidly and Require Technology Solutions
7 Global Health Problems are Growing Rapidly and Require Technology Solutions • 16 Million new stroke patients each year expected to double by 2030 and double again by 2050 • Stroke is growing worldwide, with highest incidence occurring in Asia and the Middle East • Rehabilitation robots being adopt
Slide 8: InMotion vs. conventional therapy
Assumes brain cannot recover from neurologic injury Injured brain can recover through plasticity based remapping of pathways. InMotion is a truly interactive robotic rehabilitation system harnessing good plasticity to augment recovery. Focuses on compensation. Patients have a difficult time adhering
Slide 9: Upper Extremity Products Commercially Available Today
9 Upper Extremity Products Commercially Available Today • InMotion ARM - Designed to rehabilitate stroke patients with upper body neurological limitations - Evidence based, intelligent, interactive technology capable of continuously adapting to and challenging the patient's ability - Allows the clin
Slide 10: Development-Stage Product Portfolio Addressing Upper and Lower Body
Product Optimization Pre - Clinical Clinical Key Milestones InMotion AHW V2 • Commercial l aunch Q2 2017 InMotion ANKLEBOT™ • File FDA Clearance Q3’ 17 • Launch Q1 `18 ARKE TM • Complete 2.1 clinical testing Q1 ’17; 2.5 Q1 ‘18 InMotion LIGHT • Commercial l aunch 2018 Gait Trainer • Advance developme
Slide 11: Lower Body Development-Stage Product Pipeline
11 Lower Body Development - Stage Product Pipeline • ARKE Lower Body Exoskeleton - Lower body exoskeleton designed to allow paraplegics and other wheelchair bound individuals to walk and rehabilitate - Sensors throughout the device sense body movement and trigger motion - Fully customizable to fit m
Slide 12: InMotion Products – Evidence Based and Clinically Proven
12 InMotion Products – Evidence Based and Clinically Proven • Extensive pool of research supports the clinical efficacy • Over 200 published papers reviewing use in scientific journals • Over 1000 patients have been studied in clinical trials at academic and clinical sites • Outcomes demonstrate cli
Slide 13: RATULS Trial – Expected to Positively Impact Reimbursement and Market Expansion
13 RATULS Trial – Expected to Positively Impact Reimbursement and Market Expansion • Landmark study: Largest study ever conducted with robotics for rehabilitation • Three arm randomised controlled trial designed to determine whether robot assisted training improves upper limb function post stroke us
Slide 14: The InMotion Advantage
14 The InMotion Advantage • InMotion technology assists the healthcare provider to: - Deliver progressive “assist - as - needed” individualized treatment plans - Deliver precisely reproducible and measureable treatment protocols - Treat multiple patients at the same time • Powerful clinical evaluati
Slide 15: Stroke Treatment Guidelines Recommend Robot Assisted Therapy
15 Stroke Treatment Guidelines Recommend Robot Assisted Therapy – Based on InMotion Clinical Data • By referencing clinical trials using InMotion robots, the American Heart Association (AHA) Stroke division assigned the highest possible level of recommendation for the use of robot assisted therapy f
Slide 16: US Installations and Growing List of Customers
Rehab Institute of Michigan Detroit, Michigan Frazier Rehabilitation Institute Louisville, Kentucky Baptist Medical System Memphis, Tennessee Texas State University San Marcos, Texas Cleveland Clinic Cleveland, Ohio Rancho Los Amigos Los Angeles, California VA Healthcare System Baltimore, Maryland F
Slide 17: Robotic Systems Installed Worldwide – International Customer Accounts
17 Over 250 Robotic Systems Installed Worldwide – International Customer Accounts Cardinal Santos Medical Center Philippines Rede de Reabilitação Lucy Montoro Hospital Brazil Australian NeuroRehabilitation Institute Australia McGill University Canada Fondazione Salvatore Maugeri Italy Guttman Instit
Slide 18: Bionik - Unique Market Position Versus Competition
18 Bionik - Unique Market Position Versus Competition Hocoma Cyberdyne ReWalk Ekso Indigo Myomo Commercial strategies to expand access UK Study (2018) Bionik Bionik RehaTek Access Brand Promise Value Proposition S&M Infrastructure International Distribution Contracting and Partnering Customer Suppor
Slide 19: Growth Strategy Focused on Further Pipeline Expansion
19 Growth Strategy Focused on Further Pipeline Expansion • Newly formed commercialization team expected to to build out our sales and distribution channel • Building out sales models for the product pipeline with revenue sharing and leasing strategies • Build out the company pipeline with internal d
Slide 20: Management Team
20 • Peter Bloch, CPA, CA – Chief Executive Officer • Over 25 years of executive management experience with proven track record of building public and private technology companies . F ormer CFO and joint Interim CEO of Sanofi Canada, CFO of Intellivax , Gennum TSX:GNM (n/k/a Semtech NASDAQ:SMTC), Ju
Slide 21: Board of Directors and Advisors
21 Board of Directors • Dr. Robert Hariri • Independent Director • Chairman, Founder, Chief Scientific Officer, and former Chief Executive Officer of Celgene Cellular Therapeutics; Board member of Myos Corporation and Provista Diagnostics • Marc Mathieu • Independent Director • Chief Marketing Offic
Slide 22: Financial Snapshot
22 Financial Snapshot - OTCQX: BNKL Stock Ticker Symbol OTCQX: BNKL Market Capitalization as of October 31, 2016 $72 M Shares Outstanding* 96.2 M Warrants at exercise price of $1.40 16.4 M Warrants at exercise price of $0.80 1.49 M Cash as of June 30, 2016 $2.7 M Amount received in grants to date $2
Slide 23: Execution of Near-Term Priorities Expected to Drive Value
23 Focus on revenue generation and market expansion Launch of AHW Version 2 InMotion product line Advance development products through to commercialization Further expand product portfolio through acquisitions/licensing Uplist to National Exchange Execution of Near - Term Priorities Expected to Driv
Slide 24: Investment Summary
24 Investment Summary • Proprietary robotics upper and lower body development and commercial product line focused on stroke rehabilitation and mobility solutions • Company well positioned to lead emerging markets with technology solutions addressing $11 billion addressable market • Product launch of
Slide 25: Pioneering global medical device and robotics company
25 Pioneering global medical device and robotics company focused on providing rehabilitation solutions to individuals with neurological disorders www.bioniklabs.com OTCQX:BNKL
Bionik Laboratories — Investor Presentation (November 2016) on 6ix